Propranolol
- Generic Name
- Propranolol
- Brand Names
- Hemangeol, Hemangiol, Inderal, Innopran
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 525-66-6
- Unique Ingredient Identifier
- 9Y8NXQ24VQ
- Background
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.
Propranolol was granted FDA approval on 13 November 1967.
- Indication
Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.
- Associated Conditions
- Akathisia caused by antipsychotic use, Angina Pectoris, Atrial Fibrillation, Cardiovascular Mortality, Essential Tremor, Gastroesophageal variceal hemorrhage prophylaxis, Hemangiomas, Hypertension, Migraine, Myocardial Infarction, Obstructive Hypertrophic Cardiomyopathy, Performance Anxiety, Pheochromocytoma, Proliferating Infantile Hemangioma, Supraventricular Arrhythmias, Tachyarrhythmia caused by Digitalis intoxication, Tachyarrhythmia caused by catecholamine excess, Thyroid Crisis, Thyrotoxicosis, Tremor caused by lithium, Ventricular Tachycardia (VT)
- Associated Therapies
- -
Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05679193
- Locations
- 🇳🇴
Oslo University Hospital The Norwegian Radium Hospital, Oslo, Norway
Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT05651789
Beta-Adrenergic Modulation of Drug Cue Reactivity
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 80
- Registration Number
- NCT05587361
- Locations
- 🇺🇸
Hardesty Center for Clinical Research and Neuroscience, Tulsa, Oklahoma, United States
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05561751
- Locations
- 🇺🇸
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Florida (UF) - Shands Cancer Center, Gainesville, Florida, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 62
- Registration Number
- NCT05451043
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
- Conditions
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT05429970
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Propranolol and Von Hippel-Lindau Disease
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 85
- Registration Number
- NCT05424016
- Locations
- 🇫🇷
AP-HP, Bicêtre Hospital, Le Kremlin Bicêtre, France
Propranolol on Post Stroke Immune Status and Infection
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05375240
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, China
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 175
- Registration Number
- NCT05312255
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Beta Blocker Effects in Traumatic Brain Injury
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Menoufia University
- Target Recruit Count
- 40
- Registration Number
- NCT05195996
- Locations
- 🇪🇬
Faculty of Medicine, University Hospitals, Shibīn Al Kawm, Menoufia, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.